What is William Blair’s Estimate for Genmab A/S Q3 Earnings?

Genmab A/S (NASDAQ:GMAB) – Research analysts at William Blair issued their Q3 2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts that the company will post earnings of $0.46 per share for the quarter. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. William Blair also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.44 EPS and FY2028 earnings at $4.02 EPS.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.

A number of other equities research analysts have also issued reports on the company. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $21.77 on Monday. The business’s 50 day simple moving average is $20.64 and its 200 day simple moving average is $23.02. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The firm has a market cap of $14.41 billion, a PE ratio of 21.14, a P/E/G ratio of 0.54 and a beta of 0.96.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC lifted its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC lifted its position in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.